arrow_back Back to App

Sickle Cell Disease: Awareness Day and Mandate for Equitable Access to Gene Therapies.

The US Senate supports designating June 19 as World Sickle Cell Awareness Day to boost public awareness and research efforts. The resolution calls on federal agencies, including Medicare and Medicaid, to eliminate barriers and ensure equitable access to innovative treatments, such as gene therapies, for all patients. This action aims to improve the quality of life for affected individuals and address systemic bias in healthcare.
Key points
Calls for ensuring equitable access to innovative therapies (including gene and cell therapies) for Sickle Cell Disease patients, regardless of economic or ethnic background.
Encourages the President to form an Interagency Group to develop policies that improve access to treatment within Medicare and Medicaid and address racial bias faced by affected populations.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_SRES_738
Sponsor: Sen. Booker, Cory A. [D-NJ]
Process start date: 2024-06-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

A resolution expressing support for the designation of June 19, 2024, as "World Sickle Cell Awareness Day" in order to increase public awareness across the United States and global community about sickle cell disease and the continued need for empirical research, early detection screenings, novel effective treatments leading to a cure, and preventative care programs with respect to complications from sickle cell anemia and conditions relating to sickle cell disease.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_SRES_738.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-06-18.

What are the main provisions?

Key points include:

  • Calls for ensuring equitable access to innovative therapies (including gene and cell therapies) for Sickle Cell Disease patients, regardless of economic or ethnic background.
  • Encourages the President to form an Interagency Group to develop policies that improve access to treatment within Medicare and Medicaid and address racial bias faced by affected populations.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Booker, Cory A. [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health